Cytokines and psychopathology: Lessons from interferon-α

Biological Psychiatry

Volumn 56, Issue 11, 2004, Pages 819-824

  Capuron, Lucile ^a   Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cytokines; depression; Immune system; interferon , mood disorders; pathophysiology

Indexed keywords

ALPHA INTERFERON; ANTIDEPRESSANT AGENT; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; PAROXETINE;

ANHEDONIA; ANOREXIA; APPETITE DISORDER; AUTONOMIC NEUROPATHY; BASAL GANGLION; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONFUSION; DEPRESSION; DOPAMINE METABOLISM; FATIGUE; FEAR; GASTROINTESTINAL SYMPTOM; GUILT; HUMAN; IRRITABILITY; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NEUROTOXICITY; PAIN; PHENOMENOLOGY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; PSYCHOMOTOR RETARDATION; REVIEW; SEROTONIN METABOLISM; SLEEP DISORDER; SUICIDE ATTEMPT; TENSION;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BASAL GANGLIA; BEHAVIORAL SYMPTOMS; COGNITION DISORDERS; CYTOKINES; HUMANS; HYDROCORTISONE; INTERFERON-ALPHA; MODELS, IMMUNOLOGICAL; PSYCHOPATHOLOGY; SEROTONIN;

EID: 9644276925     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.02.009     Document Type: Review

References (36)

1. Berger J.R., Arendt G. HIV dementia The role of the basal ganglia and dopaminergic systems. J Psychopharmacol. 14:2000;214-221
2. Besedovsky H.O., del Rey A. Immune-neuro-endocrine interactions Facts and hypotheses. Endocr Rev. 17:1996;64-102
3. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivor. Psychosom Med. 64:2002;604-611
4. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-alpha in cancer patients Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 26:2002;643-652
5. Capuron L., Neurauter G., Lawson D.H., Musselman D.L., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism Relationships to depression and paroxetine treatment. Biol Psychiatry. 54:2003;906-914
6. Capuron L., Pagnoni G., Lawson D.H., Demetrashvili M., Woolwine B.J., Kilts C.D., et al. Altered fronto-pallidal activity during high-dose interferon-alpha treatment as determined by positron emission tomography. Abstr Soc Neurosci. 498:2002;5
7. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry. 160:2003;1342-1345
8. Cleeland C.S., Bennett G.J., Dantzer R., Dougherty P.M., Dunn A.J., Meyers C.A., et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 97:2003;2919-2925
9. Dantzer R., Wollman E.E., Yirmiya R. Cytokines, Stress, and Depression. 1999;Plenum, Kluwer Academic, New York
10. Delgado P.L., Charney D.S., Price L.H., Aghajanian G.K., Landis H., Heninger G.R. Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry. 47:1990;411-418
11. Evans D.L., Staab J.P., Petitto J.M., Morrison M.F., Szuba M.P., Ward H.E., et al. Depression in the medical setting Biopsychological interactions and treatment considerations. J Clin Psychiatry. 60:(suppl 4):1999;40-56
12. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons Relevance to Parkinson's disease. J Neurochem. 81:2002;1285-1297
13. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage. 8:1993;196-200
14. Haas H.S., Schauenstein K. Neuroimmunomodulation via limbic structures The neuroanatomy of psychoimmunology. Prog Neurobiol. 51:1997;195-222
15. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA. 284:2000;592-597
16. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501
17. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl). 152:2000;383-389
18. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol. 10:2000;129-132
19. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behavior Mechanisms and implications. Trends Neurosci. 25:2002;154-159
20. Lou J.S., Kearns G., Benice T., Oken B., Sexton G., Nutt J. Levodopa improves physical fatigue in Parkinson's disease A double-blind, placebo-controlled, crossover study. Mov Disord. 18:2003;1108-1114
21. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol. 461:1999;25-46
22. Martinot M., Bragulat V., Artiges E., Dolle F., Hinnen F., Jouvent R., et al. Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation. Am J Psychiatry. 158:2001;314-316
23. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance Immunosuppression by starvation? Immunol Today. 20:1999;469-473
24. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L., Flynn P.J., et al. Differential effects of paroxetine on fatigue and depression A randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol. 21:2003;4635-4641
25. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 344:2001;961-966
26. Musselman D.L., Miller A.H., Porter M.R., Manatunga A.K., Gao F., Penna S., et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression Preliminary findings. Am J Psychiatry. 158:2001;1252-1257
27. Owens M.J., Nemeroff C.B. The role of corticotropin-releasing-factor in the pathophysiology of affective and anxiety disorders Laboratory and clinical studies. Ciba Found Symp. 172:1993;296-308
28. Raber J., Koob G.F., Bloom F.E. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala Comparison with the hypothalamic response. Neurochem Int. 30:1997;455-463
29. Raison C.L., Miller A.H. Depression in cancer New developments regarding diagnosis and treatment. Biol Psychiatry. 54:2003;283-294
30. Reichenberg A., Kraus T., Haack M., Schuld A., Pollmacher T., Yirmiya R. Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion. Psychoneuroendocrinology. 27:2002;945-956
31. Rye D.B., Jankovic J. Emerging views of dopamine in modulating sleep/wake state from an unlikely source PD. Neurology. 58:2002;341-346
32. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 747:1997;348-351
33. Spath-Schwalbe E., Hansen K., Schmidt F., Schrezenmeier H., Marshall L., Burger K., et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 83:1998;1573-1579
34. Sunami M., Nishikawa T., Yorogi A., Shimoda M. Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha. Clin Neuropharmacol. 23:2000;59-61
35. Taylor J.L., Grossberg S.E. The effects of interferon-alpha on the production and action of other cytokines. Semin Oncol. 25:(suppl 1):1998;23-29
36. Yamano M., Yuki H., Yasuda S., Miyata K. Corticotropin-releasing hormone receptors mediate consensus interferon-alpha YM643-induced depression-like behavior in mice. J Pharmacol Exp Ther. 292:2000;181-187